Skip to main content

Townsend Adam J.'s Form 4 filing

Apellis Pharmaceuticals, Inc. (APLS) · filed Aug 12, 2022

Accession no.
0001127602-22-020889
Filed
Aug 12, 2022
Trade date
Aug 11, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $837.5K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Townsend Adam J.CIK 0001773588Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 11, 2022Common StockMOption exerciseAcquired+12,500$15.09+$188,62555,407Direct
Aug 11, 2022Common StockSSaleDisposed−12,500$67.00−$837,50042,907Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 11, 2022Common StockMOption exerciseDisposed−12,500$0.00$0340,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)